H.R. 5708 · 118th Congress (2023–2025)
MCM PRV Reauthorization Act
To amend the Federal Food, Drug, and Cosmetic Act to extend a priority review program to encourage treatments for agents that present national security threats.
CRS summary not yet available.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 5708’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Brad Finstad (R-MN-1)
- Cosponsors
1 cosponsor
1 original · 0 later
- Rep. Dean Phillips (D-MN-3)· Original · Sep 26, 2023
- Policy area
- Health
- Subjects
- Chemical and biological weapons
- Health technology, devices, supplies
- Infectious and parasitic diseases
- Licensing and registrations
- Prescription drugs
- User charges and fees
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Sep 26, 2023 – Sep 29, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
MCM PRV Reauthorization Act
Display title, Short title · Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to extend a priority review program to encourage treatments for agents that present national security threats.
Official title · Introduced in House